CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors
Tóm tắt
Patients with relapsed pediatric solid tumors and CNS malignancies have few therapeutic options and frequently die of their disease. Chimeric antigen receptor (CAR) T cells have shown tremendous success in treating relapsed pediatric acute lymphoblastic leukemia, but this has not yet translated to treating solid tumors. This is partially due to a paucity of differentially expressed cell surface molecules on solid tumors that can be safely targeted. Here, we present B7-H3 (CD276) as a putative target for CAR T-cell therapy of pediatric solid tumors, including those arising in the central nervous system.
We developed a novel B7-H3 CAR whose binder is derived from a mAb that has been shown to preferentially bind tumor tissues and has been safely used in humans in early-phase clinical trials. We tested B7-H3 CAR T cells in a variety of pediatric cancer models.
B7-H3 CAR T cells mediate significant antitumor activity in vivo, causing regression of established solid tumors in xenograft models including osteosarcoma, medulloblastoma, and Ewing sarcoma. We demonstrate that B7-H3 CAR T-cell efficacy is largely dependent upon high surface target antigen density on tumor tissues and that activity is greatly diminished against target cells that express low levels of antigen, thus providing a possible therapeutic window despite low-level normal tissue expression of B7-H3.
B7-H3 CAR T cells could represent an exciting therapeutic option for patients with certain lethal relapsed or refractory pediatric malignancies, and should be tested in carefully designed clinical trials.
Từ khóa
Tài liệu tham khảo
Smith, 2014, Declining childhood and adolescent cancer mortality, Cancer, 120, 2497, 10.1002/cncr.28748
Perkins, 2014, Outcome for children with metastatic solid tumors over the last four decades, PLoS One, 9, e100396, 10.1371/journal.pone.0100396
Packer, 2008, Childhood brain tumors: accomplishments and ongoing challenges, J Child Neurol, 23, 1122, 10.1177/0883073808320758
Rodriguez-Galindo, 2002, Survival after recurrence of Ewing tumors: the St Jude Children's Research Hospital experience, 1979–1999, Cancer, 94, 561, 10.1002/cncr.10192
Tomlinson, 1992, Medulloblastoma: I. Clinical, diagnostic, and therapeutic overview, J Child Neurol, 7, 142, 10.1177/088307389200700203
Ebb, 2012, Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the Children's Oncology Group, J Clin Oncol, 30, 2545, 10.1200/JCO.2011.37.4546
Pappo, 2014, A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: results of a Sarcoma Alliance for Research Through Collaboration study, Cancer, 120, 2448, 10.1002/cncr.28728
Postow, 2015, Nivolumab and ipilimumab versus ipilimumab in untreated melanoma, N Engl J Med, 372, 2006, 10.1056/NEJMoa1414428
Davis, 2017, ADVL1412: Initial results of a phase I/II study of nivolumab and ipilimumab in pediatric patients with relapsed/refractory solid tumors—A COG study, J Clin Oncol, 35, 10526, 10.1200/JCO.2017.35.15_suppl.10526
Majzner, 2017, Harnessing the immunotherapy revolution for the treatment of childhood cancers, Cancer Cell, 31, 476, 10.1016/j.ccell.2017.03.002
Majzner, 2017, Assessment of programmed death-ligand 1 expression and tumor-associated immune cells in pediatric cancer tissues, Cancer, 123, 3807, 10.1002/cncr.30724
Mackall, 2014, Immune-based therapies for childhood cancer, Nat Rev Clin Oncol, 11, 693, 10.1038/nrclinonc.2014.177
Lee, 2015, T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial, Lancet, 385, 517, 10.1016/S0140-6736(14)61403-3
Maude, 2014, Chimeric antigen receptor T cells for sustained remissions in leukemia, N Engl J Med, 371, 1507, 10.1056/NEJMoa1407222
Gardner, 2017, Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults, Blood, 129, 3322, 10.1182/blood-2017-02-769208
Ahmed, 2015, Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma, J Clin Oncol, 33, 1688, 10.1200/JCO.2014.58.0225
Ahmed, 2017, HER2-specific chimeric antigen receptor-modified virus-specific T cells for progressive glioblastoma: a phase 1 dose-escalation trial, JAMA Oncol, 3, 1094, 10.1001/jamaoncol.2017.0184
Walker, 2017, Tumor antigen and receptor densities regulate efficacy of a chimeric antigen receptor targeting anaplastic lymphoma kinase, Mol Ther, 25, 2189, 10.1016/j.ymthe.2017.06.008
Caruso, 2015, Tuning sensitivity of CAR to EGFR density limits recognition of normal tissue while maintaining potent antitumor activity, Cancer Res, 75, 3505, 10.1158/0008-5472.CAN-15-0139
Liu, 2015, Affinity-tuned ErbB2 or EGFR chimeric antigen receptor T cells exhibit an increased therapeutic index against tumors in mice, Cancer Res, 75, 3596, 10.1158/0008-5472.CAN-15-0159
Majzner, 2018, Tumor antigen escape from CAR T-cell therapy, Cancer Discov, 8, 1219, 10.1158/2159-8290.CD-18-0442
Maus, 2016, Making better chimeric antigen receptors for adoptive T-cell therapy, Clin Cancer Res, 22, 1875, 10.1158/1078-0432.CCR-15-1433
Wang, 2013, B7-H3 is overexpressed in patients suffering osteosarcoma and associated with tumor aggressiveness and metastasis, PLoS One, 8, e70689, 10.1371/journal.pone.0070689
Zhou, 2013, B7-H3, a potential therapeutic target, is expressed in diffuse intrinsic pontine glioma, J Neurooncol, 111, 257, 10.1007/s11060-012-1021-2
Modak, 2001, Monoclonal antibody 8H9 targets a novel cell surface antigen expressed by a wide spectrum of human solid tumors, Cancer Res, 61, 4048
Picarda, 2016, Molecular pathways: targeting B7-H3 (CD276) for human cancer immunotherapy, Clin Cancer Res, 22, 3425, 10.1158/1078-0432.CCR-15-2428
Tekle, 2012, B7-H3 contributes to the metastatic capacity of melanoma cells by modulation of known metastasis-associated genes, Int J Cancer, 130, 2282, 10.1002/ijc.26238
Ye, 2016, B7-H3 Overexpression predicts poor survival of cancer patients: a meta-analysis, Cell Physiol Biochem, 39, 1568, 10.1159/000447859
Kramer, 2010, Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma, J Neurooncol, 97, 409, 10.1007/s11060-009-0038-7
Loo, 2012, Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity, Clin Cancer Res, 18, 3834, 10.1158/1078-0432.CCR-12-0715
Powderly, 2015, Interim results of an ongoing phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3, J Immunother Cancer, 3, O8, 10.1186/2051-1426-3-S2-O8
Souweidane, 2018, Convection-enhanced delivery for diffuse intrinsic pontine glioma: a single-centre, dose-escalation, phase 1 trial, Lancet Oncol, 19, 1040, 10.1016/S1470-2045(18)30322-X
Modak, 2018, Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14–18; Chicago, IL, Intraperitoneal radioimmunotherapy for desmoplastic small round cell tumor: Results of a phase I study (NCT01099644)
Lin, 2017, A protocol for rapid post-mortem cell culture of diffuse intrinsic pontine glioma (DIPG), J Vis Exp, 121, 55360
Seaman, 2017, Eradication of tumors through simultaneous ablation of CD276/B7-H3-positive tumor cells and tumor vasculature, Cancer Cell, 31, 501, 10.1016/j.ccell.2017.03.005
Mount, 2018, Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M(+) diffuse midline gliomas, Nat Med, 24, 572, 10.1038/s41591-018-0006-x
Nellan, 2018, Durable regression of medulloblastoma after regional and intravenous delivery of anti-HER2 chimeric antigen receptor T cells, J Immunother Cancer, 6, 30, 10.1186/s40425-018-0340-z
Zhang, 2016, Anti-CD47 treatment stimulates phagocytosis of glioblastoma by M1 and M2 polarized macrophages and promotes M1 polarized macrophages in vivo, PLoS One, 11, e0153550, 10.1371/journal.pone.0153550
Long, 2015, 4–1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors, Nat Med, 21, 581, 10.1038/nm.3838
Ren, 2015, Characterization of the metastatic phenotype of a panel of established osteosarcoma cells, Oncotarget, 6, 29469, 10.18632/oncotarget.5177
Gholamin, 2017 15, Disrupting the CD47-SIRPalpha anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors, Sci Transl Med, 9, 10.1126/scitranslmed.aaf2968
Guery, 2015, B7-H3 protein expression in acute myeloid leukemia, Cancer Med, 4, 1879, 10.1002/cam4.522
Sotillo, 2015, Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy, Cancer Discov, 5, 1282, 10.1158/2159-8290.CD-15-1020
O'Rourke, 2017, A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma, Sci Transl Med, 9
Ahmed, 2015, Humanized affinity-matured monoclonal antibody 8H9 has potent antitumor activity and binds to FG loop of tumor antigen B7-H3, J Biol Chem, 290, 30018, 10.1074/jbc.M115.679852
Chapoval, 2001, B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production, Nat Immunol, 2, 269, 10.1038/85339
Luo, 2004, B7-H3 enhances tumor immunity in vivo by costimulating rapid clonal expansion of antigen-specific CD8+ cytolytic T cells, J Immunol, 173, 5445, 10.4049/jimmunol.173.9.5445
Veenstra, 2015, B7-H3 expression in donor T cells and host cells negatively regulates acute graft-versus-host disease lethality, Blood, 125, 3335, 10.1182/blood-2014-09-603357
Steinberger, 2004, Molecular characterization of human 4Ig-B7-H3, a member of the B7 family with four Ig-like domains, J Immunol, 172, 2352, 10.4049/jimmunol.172.4.2352
Fry, 2017, CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy, Nat Med, 24, 20, 10.1038/nm.4441
Kochenderfer, 2009, Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor, J Immunother, 32, 689, 10.1097/CJI.0b013e3181ac6138
Brentjens, 2003, Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15, Nat Med, 9, 279, 10.1038/nm827
Brown, 2016, Regression of glioblastoma after chimeric antigen receptor t-cell therapy, N Engl J Med, 375, 2561, 10.1056/NEJMoa1610497
Kramer, 2014, Safety profile of long-term intraventricular access devices in pediatric patients receiving radioimmunotherapy for central nervous system malignancies, Pediatr Blood Cancer, 61, 1590, 10.1002/pbc.25080
Roybal, 2016, Precision tumor recognition by T cells with combinatorial antigen-sensing circuits, Cell, 164, 770, 10.1016/j.cell.2016.01.011